Gastrointestinal stromal tumor targeted drugs

Imatinib, sunitinib, regofenib, etc. are targeted drugs for gastrointestinal stromal tumors.

1. Imatinib

, as a first-generation targeted drug, has significant efficacy in the treatment of gastrointestinal stromal tumors by inhibiting tyrosine kinase activity and blocking tumor cell proliferation signals, especially for patients with advanced inoperable or high risk of postoperative recurrence.

2. Sunitinib

, a multi-target tyrosine kinase inhibitor, can inhibit the activity of multiple tyrosine kinase receptors, inhibit tumor proliferation and block tumor angiogenesis, providing a new treatment option for patients with gastrointestinal stromal tumors.

3. Regofenib,

as a second-line treatment drug after imatinib resistance, plays an important role in the treatment of gastrointestinal stromal tumors by inhibiting tumor angiogenesis, controlling tumor development and prolonging patient survival

.